| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18699 R79538 |
Mazzone (Carbamazepine) (Controls exposed to LTG) (Mixed indications), 2025 | Apgar 5 min <7 | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.94 [0.54;1.62] C excluded (control group) |
18/600 47/1,469 | 65 | 600 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18700 R79546 |
Mazzone (Carbamazepine) (Controls unexposed, NOS) (Mixed indications), 2025 | Apgar 5 min <7 | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 1.05 [0.59;1.85] | 18/600 16,343/624,794 | 16,361 | 600 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9760 R34845 |
Bank (Carbamazepine) (Mixed indications), 2017 | Apgar < 7 at 5 minutes | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 4.73 [0.09;258.01] C | 0/8 0/36 | 0 | 8 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9757 R34839 |
Christensen (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2015 | Low Apgar score (≤ 7) at 5 min | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
2.32 [0.94;5.77] C excluded (control group) |
9/344 10/875 | 19 | 344 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9758 R34840 |
Christensen (Carbamazepine) (Controls unexposed NOS) (Mixed indications), 2015 | Low Apgar score (≤ 7) at 5 min | during pregnancy (anytime or not specified) | population based cohort propective | unexposed (general population or NOS) excluded | Adjustment: No |
2.00 [1.06;3.80] excluded (control group) |
9/344 8,797/674,115 | 8,806 | 344 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9759 R34841 |
Christensen (Carbamazepine) (Controls unexposed, sick) (Mixed indications), 2015 | Low Apgar score (≤ 7) at 5 min | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: No | 2.08 [1.03;4.21] C | 9/344 67/5,261 | 76 | 344 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9598 R33994 |
Artama (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013 | 5-min Apgar <7 | 3rd trimester | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.35 [0.06;2.12] C excluded (control group) |
2/248 3/132 | 5 | 248 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9599 R34006 |
Artama (Carbamazepine) (Controls unexposed, disease free), 2013 | 5-min Apgar <7 | 3rd trimester | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
0.85 [0.21;3.42] excluded (control group) |
2/248 3,014/269,151 | 3,016 | 248 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9600 R34018 |
Artama (Carbamazepine) (Controls unexposed, sick), 2013 | 5-min Apgar <7 | 3rd trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 1.08 [0.20;5.15] | 2/248 3/652 | 5 | 248 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9743 R34759 |
Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) b, 2013 | Low Apgar score (< 7 at 5 min) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.30 [0.01;6.40] C excluded (control group) |
0/67 2/103 | 2 | 67 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9745 R34778 |
Veiby (Carbamazepine) (Controls unexposed, disease free) b, 2013 | Low Apgar score (< 7 at 5 min) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
0.46 [0.03;7.47] C excluded (control group) |
0/67 1,710/106,899 | 1,710 | 67 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9746 R34792 |
Veiby (Carbamazepine) (Controls unexposed, sick) b, 2013 | Low Apgar score (< 7 at 5 min) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 0.30 [0.02;5.18] C | 0/67 9/386 | 9 | 67 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9640 R34298 |
Pennell (Carbamazepine), 2012 | Apgar score (at 5 minutes < 7) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 3.23 [0.13;80.44] C | 1/91 0/97 | 1 | 91 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9751 R34820 |
Borthen (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2010 | Apgar < 7 after 5 minutes | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.94 [0.36;2.46] C excluded (control group) |
11/388 7/233 | 18 | 388 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9753 R34828 |
Borthen (Carbamazepine) (Controls unexposed, disease free), 2010 | Apgar < 7 after 5 minutes | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
1.70 [0.90;3.10] excluded (control group) |
11/388 6,022/362,302 | 6,033 | 388 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9755 R34836 |
Borthen (Carbamazepine) (Controls unexposed, sick), 2010 | Apgar < 7 after 5 minutes | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No | 1.78 [0.89;3.59] C | 11/388 30/1,863 | 41 | 388 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 7 studies | 1.45 [1.01;2.08] | 16,493 | 1,746 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Carbamazepine) (Controls unexposed, NOS) (Mixed indications; 2: Carbamazepine) (Mixed indications; 3: Carbamazepine) (Controls unexposed, sick) (Mixed indications; 4: Carbamazepine) (Controls unexposed, sick; 5: Carbamazepine) (Controls unexposed, sick) ; 6: Carbamazepine; 7: Carbamazepine) (Controls unexposed, sick;
Asymetry test p-value = 0.9493 (by Egger's regression)
slope=0.3556 (0.3095); intercept=0.0427 (0.6395); t=0.0668; p=0.9493
excluded 9751, 9753, 9598, 9599, 9743, 9745, 9757, 9758, 18699